Shots:

• Sanofi and Regeneron will simplify their Ab collaboration for Kevzara and Praluent by restructuring into a royalty-based agreement
• Under the proposed restructuring- Sanofi is expected to get WW rights for Kevzara and (Ex-US) rights for Praluent while Regeneron is expected to get US rights for Praluent. The companies will be responsible to fund development and commercialization expenses in their respective territories
• The restructuring of an agreement will lead to increase efficiency and streamline operations for the products with its anticipated completion in Q1’20. The existing collaboration regarding Dupixent (dupilumab) will remain unchanged following the restructuring

Click here to­ read full press release/ article | Ref: Regeneron | Image: Contract Pharma